T. Rowe Price Associates
SPHS

T. Rowe Price Associates’s Sophiris Bio, Inc. SPHS Stock Holding History

T. Rowe Price Associates’s Portfolio SPHS Stock Details SPHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,609,928
Closed -$4.72M – 2624
2014
Q3 		$4.72M Sell
1,609,928
-3,400
-0.2% -$9.57K ﹤0.01% 1465
2014
Q2 		$3.61M Sell
1,613,328
-900
-0.1% -$2.66K ﹤0.01% 1493
2014
Q1 		$5.38M Hold
1,614,228
– – ﹤0.01% 1424
2013
Q4 		$5.97M Hold
1,614,228
– – ﹤0.01% 1407
2013
Q3 		$7.54M Buy
+1,614,228
New +$7.44M ﹤0.01% 1336

Other funds holding SPHS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

T. Rowe Price Associates's SPHS Position: Q4 2014 in Review

T. Rowe Price Associates sold out of Sophiris Bio, Inc. (SPHS) in Q4 2014, closing a stake of 1,609,928 shares — an estimated $4.72M sold.

T. Rowe Price Associates first reported a position in SPHS in Q3 2013 and held it in 5 quarters. The position peaked at $7.54M in Q3 2013. 14 funds tracked by Wall St. Rank hold SPHS as of Q4 2014.

  • T. Rowe Price Associates reported no remaining Sophiris Bio, Inc. position as of Q4 2014 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,609,928 Sophiris Bio, Inc. shares in Q4 2014, an estimated $4.72M.
  • T. Rowe Price Associates first reported a position in Sophiris Bio, Inc. in Q3 2013 and held it in 5 quarters.
  • T. Rowe Price Associates's Sophiris Bio, Inc. position peaked at $7.54M in Q3 2013.
  • 14 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q4 2014.

Based on T. Rowe Price Associates's 13F filing for Q4 2014, filed 13 Feb 2015.